Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Use of ankle immobilization in evaluating treatments to promote longitudinal muscle growth in mice.

Tinklenberg J, Beatka M, Bain JL, Siebers EM, Meng H, Pearsall RS, Lawlor MW, Riley DA.

Muscle Nerve. 2018 Jul 7. doi: 10.1002/mus.26296. [Epub ahead of print]

PMID:
29981243
2.

Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Jeong Y, Daghlas SA, Xie Y, Hulbert MA, Pfeiffer FM, Dallas MR, Omosule CL, Pearsall RS, Dallas SL, Phillips CL.

J Bone Miner Res. 2018 May 29. doi: 10.1002/jbmr.3473. [Epub ahead of print]

PMID:
29813187
3.

Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.

Jeong Y, Daghlas SA, Kahveci AS, Salamango D, Gentry BA, Brown M, Rector RS, Pearsall RS, Phillips CL.

Muscle Nerve. 2018 Feb;57(2):294-304. doi: 10.1002/mus.25706. Epub 2017 Jun 15.

PMID:
28555931
4.

A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension.

Yung LM, Nikolic I, Paskin-Flerlage SD, Pearsall RS, Kumar R, Yu PB.

Am J Respir Crit Care Med. 2016 Nov 1;194(9):1140-1151.

5.

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.

Wang X, Solban N, Khanna P, Callea M, Song J, Alsop DC, Pearsall RS, Atkins MB, Mier JW, Signoretti S, Alimzhanov M, Kumar R, Bhasin MK, Bhatt RS.

Oncotarget. 2016 Jul 5;7(27):41857-41869. doi: 10.18632/oncotarget.9621.

6.

Treatment with ActRIIB-mFc Produces Myofiber Growth and Improves Lifespan in the Acta1 H40Y Murine Model of Nemaline Myopathy.

Tinklenberg J, Meng H, Yang L, Liu F, Hoffmann RG, Dasgupta M, Allen KP, Beggs AH, Hardeman EC, Pearsall RS, Fitts RH, Lawlor MW.

Am J Pathol. 2016 Jun;186(6):1568-81. doi: 10.1016/j.ajpath.2016.02.008. Epub 2016 Apr 18.

7.

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.

Cunha SI, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, Lindström L, Bartoschek M, Haller BK, Pearsall RS, Mulivor AW, Kumar R, Larsson C, Bergh J, Pietras K.

Cancer Res. 2015 Jun 15;75(12):2445-56. doi: 10.1158/0008-5472.CAN-14-3706. Erratum in: Cancer Res. 2016 Oct 15;76(20):6131-6132.

8.

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.

Suragani RN, Cawley SM, Li R, Wallner S, Alexander MJ, Mulivor AW, Gardenghi S, Rivella S, Grinberg AV, Pearsall RS, Kumar R.

Blood. 2014 Jun 19;123(25):3864-72. doi: 10.1182/blood-2013-06-511238. Epub 2014 May 2.

9.

Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.

Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R.

Nat Med. 2014 Apr;20(4):408-14. doi: 10.1038/nm.3512. Epub 2014 Mar 23.

PMID:
24658078
10.

Mapping six new susceptibility to colon cancer (Scc) loci using a mouse interspecific backcross.

Eversley CD, Yuying X, Pearsall RS, Threadgill DW.

G3 (Bethesda). 2012 Dec;2(12):1577-84. doi: 10.1534/g3.112.002253. Epub 2012 Dec 1.

11.

A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength.

Baud'huin M, Solban N, Cornwall-Brady M, Sako D, Kawamoto Y, Liharska K, Lath D, Bouxsein ML, Underwood KW, Ucran J, Kumar R, Pobre E, Grinberg A, Seehra J, Canalis E, Pearsall RS, Croucher PI.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12207-12. doi: 10.1073/pnas.1204929109. Epub 2012 Jul 3.

12.

Activin receptor signaling: a potential therapeutic target for osteoporosis.

Lotinun S, Pearsall RS, Horne WC, Baron R.

Curr Mol Pharmacol. 2012 Jun;5(2):195-204. Review.

PMID:
21787285
13.

Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.

Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, Sako D, Pearsall RS, Underwood KW, Seehra J, Kumar R, Grinberg AV.

J Biol Chem. 2011 Aug 26;286(34):30034-46. doi: 10.1074/jbc.M111.260133. Epub 2011 Jul 7.

14.

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL.

J Appl Physiol (1985). 2010 Sep;109(3):635-42. doi: 10.1152/japplphysiol.00866.2009. Epub 2010 May 13.

15.

Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb.

Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, Andreucci AJ, Pobre EG, Tomkinson KN, Monnell TE, Ucran JA, Martinez-Hackert E, Pearsall RS, Underwood KW, Seehra J, Kumar R.

J Biol Chem. 2010 Jul 2;285(27):21037-48. doi: 10.1074/jbc.M110.114959. Epub 2010 Apr 12.

16.

ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.

Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R.

Mol Cancer Ther. 2010 Feb;9(2):379-88. doi: 10.1158/1535-7163.MCT-09-0650. Epub 2010 Feb 2.

17.

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys.

Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J, Bouxsein ML, Baron R.

Bone. 2010 Apr;46(4):1082-8. doi: 10.1016/j.bone.2010.01.370. Epub 2010 Jan 18.

PMID:
20080223
18.

Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis).

Fajardo RJ, Manoharan RK, Pearsall RS, Davies MV, Marvell T, Monnell TE, Ucran JA, Pearsall AE, Khanzode D, Kumar R, Underwood KW, Roberts B, Seehra J, Bouxsein ML.

Bone. 2010 Jan;46(1):64-71. doi: 10.1016/j.bone.2009.09.018. Epub 2009 Sep 23.

PMID:
19781677
19.

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein ML.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):7082-7. doi: 10.1073/pnas.0711263105. Epub 2008 May 6.

20.

Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet.

Bissahoyo A, Pearsall RS, Hanlon K, Amann V, Hicks D, Godfrey VL, Threadgill DW.

Toxicol Sci. 2005 Dec;88(2):340-5. Epub 2005 Sep 8.

PMID:
16150884
21.

Identification of MAGI-3 as a transforming growth factor-alpha tail binding protein.

Franklin JL, Yoshiura K, Dempsey PJ, Bogatcheva G, Jeyakumar L, Meise KS, Pearsall RS, Threadgill D, Coffey RJ.

Exp Cell Res. 2005 Feb 15;303(2):457-70.

PMID:
15652357
22.

Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage.

Lee D, Pearsall RS, Das S, Dey SK, Godfrey VL, Threadgill DW.

Mol Cell Biol. 2004 Oct;24(20):8907-16.

23.

Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry.

Chaurand P, DaGue BB, Pearsall RS, Threadgill DW, Caprioli RM.

Proteomics. 2001 Oct;1(10):1320-6.

PMID:
11721643
24.

Genetic analysis of testis weight and fertility in an interspecies hybrid congenic strain for Chromosome X.

Elliott RW, Miller DR, Pearsall RS, Hohman C, Zhang Y, Poslinski D, Tabaczynski DA, Chapman VM.

Mamm Genome. 2001 Jan;12(1):45-51.

PMID:
11178743
25.

Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms.

Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, Sinclair CS, Pearsall RS, Green PJ, Yee D, Lampland AL, Balasubramaniam S, Crossley TD, Magnuson TR, James CD, Maihle NJ.

Genomics. 2001 Jan 1;71(1):1-20. Erratum in: Genomics. 2010 Aug;96(2):128.

PMID:
11161793
26.

Genetic dissection of X-linked interspecific hybrid placental dysplasia in congenic mouse strains.

Hemberger MC, Pearsall RS, Zechner U, Orth A, Otto S, Rüschendorf F, Fundele R, Elliott R.

Genetics. 1999 Sep;153(1):383-90.

27.

A direct repeat sequence at the Rasgrf1 locus and imprinted expression.

Pearsall RS, Plass C, Romano MA, Garrick MD, Shibata H, Hayashizaki Y, Held WA.

Genomics. 1999 Jan 15;55(2):194-201.

PMID:
9933566
28.

Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain.

Cooper PR, Smilinich NJ, Day CD, Nowak NJ, Reid LH, Pearsall RS, Reece M, Prawitt D, Landers J, Housman DE, Winterpacht A, Zabel BU, Pelletier J, Weissman BE, Shows TB, Higgins MJ.

Genomics. 1998 Apr 1;49(1):38-51.

PMID:
9570947
29.

A methylation imprint mark in the mouse imprinted gene Grf1/Cdc25Mm locus shares a common feature with the U2afbp-rs gene: an association with a short tandem repeat and a hypermethylated region.

Shibata H, Yoda Y, Kato R, Ueda T, Kamiya M, Hiraiwa N, Yoshiki A, Plass C, Pearsall RS, Held WA, Muramatsu M, Sasaki H, Kusakabe M, Hayashizaki Y.

Genomics. 1998 Apr 1;49(1):30-7.

PMID:
9570946
30.

The Rasgrf1-repeat sequence (D9Ncvs53) maps between Mod1 and Rbp1 on mouse chromosome 9 and may define a putative imprinted region.

Pearsall RS, Imai K, Shibata H, Hayashizaki Y, Chapman VM, Held WA, Plass C.

Mamm Genome. 1998 Mar;9(3):261-2. No abstract available.

PMID:
9501318
31.

Absence of imprinting in U2AFBPL, a human homologue of the imprinted mouse gene U2afbp-rs.

Pearsall RS, Shibata H, Brozowska A, Yoshino K, Okuda K, deJong PJ, Plass C, Chapman VM, Hayashizaki Y, Held WA.

Biochem Biophys Res Commun. 1996 May 6;222(1):171-7.

PMID:
8630064

Supplemental Content

Loading ...
Support Center